PL1761541T3 - Pochodne pirazolopirymidyny - Google Patents

Pochodne pirazolopirymidyny

Info

Publication number
PL1761541T3
PL1761541T3 PL05754665T PL05754665T PL1761541T3 PL 1761541 T3 PL1761541 T3 PL 1761541T3 PL 05754665 T PL05754665 T PL 05754665T PL 05754665 T PL05754665 T PL 05754665T PL 1761541 T3 PL1761541 T3 PL 1761541T3
Authority
PL
Poland
Prior art keywords
pyrrazolo
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
PL05754665T
Other languages
English (en)
Inventor
Erwin Goetschi
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL1761541T3 publication Critical patent/PL1761541T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL05754665T 2004-06-21 2005-06-13 Pochodne pirazolopirymidyny PL1761541T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04102837 2004-06-21
EP05754665A EP1761541B1 (en) 2004-06-21 2005-06-13 Pyrrazolo-pyrimidine derivatives
PCT/EP2005/006302 WO2005123738A1 (en) 2004-06-21 2005-06-13 Pyrrazolo-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
PL1761541T3 true PL1761541T3 (pl) 2008-06-30

Family

ID=34971089

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05754665T PL1761541T3 (pl) 2004-06-21 2005-06-13 Pochodne pirazolopirymidyny

Country Status (26)

Country Link
US (1) US7378417B2 (pl)
EP (1) EP1761541B1 (pl)
JP (1) JP4608542B2 (pl)
CN (1) CN100528876C (pl)
AR (1) AR049521A1 (pl)
AT (1) ATE383361T1 (pl)
AU (1) AU2005254657B2 (pl)
BR (1) BRPI0512330A (pl)
CA (1) CA2571487C (pl)
DE (1) DE602005004287T2 (pl)
DK (1) DK1761541T3 (pl)
ES (1) ES2299044T3 (pl)
HK (1) HK1105971A1 (pl)
HR (1) HRP20080070T3 (pl)
IL (1) IL179736A (pl)
MX (1) MXPA06014809A (pl)
MY (1) MY143368A (pl)
NO (1) NO20070249L (pl)
NZ (1) NZ551660A (pl)
PL (1) PL1761541T3 (pl)
PT (1) PT1761541E (pl)
RU (1) RU2378277C2 (pl)
SI (1) SI1761541T1 (pl)
TW (1) TWI301835B (pl)
WO (1) WO2005123738A1 (pl)
ZA (1) ZA200610102B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100968291B1 (ko) * 2005-02-11 2010-07-07 에프. 호프만-라 로슈 아게 Ｍｇｌｕｒ２ 길항제로서의 피라졸로-피리미딘 유도체
KR100973609B1 (ko) 2005-03-23 2010-08-03 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ2 길항제로서 아세틸렌일-피라졸로-피리미딘유도체
WO2007039439A1 (en) 2005-09-27 2007-04-12 F.Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
CA2626742A1 (en) * 2005-10-21 2007-04-26 Exelixis, Inc. Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
US8461162B2 (en) * 2007-07-20 2013-06-11 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives
SG194397A1 (en) * 2008-10-31 2013-11-29 Genentech Inc Pyrazolopyrimidine jak inhibitor compounds and methods
AR078171A1 (es) 2009-09-15 2011-10-19 Sanofi Aventis Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas
WO2012075393A2 (en) * 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
PT3366688T (pt) 2010-12-08 2022-05-11 Us Health Pirazolopirimidinas substituídas como ativadores de glucocerebrosidase
WO2012149157A2 (en) 2011-04-26 2012-11-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2013148333A1 (en) 2012-03-28 2013-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Salicylic acid derivatives useful as glucocerebrosidase activators
AU2013336863A1 (en) 2012-10-23 2015-03-19 F. Hoffmann-La Roche Ag MGlu2/3 antagonists for the treatment of autistic disorders
US10392389B2 (en) 2012-10-25 2019-08-27 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
WO2014066743A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
EP3134089A2 (en) 2014-04-23 2017-03-01 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of intellectual disabilities
JOP20150179B1 (ar) * 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US10570135B2 (en) 2014-11-06 2020-02-25 Lysosomal Therapeutics Inc. Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders
WO2016073891A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
AU2015357169B2 (en) 2014-12-03 2021-03-04 Janssen Pharmaceutica Nv Radiolabelled mGluR2 PET ligands
US10738016B2 (en) 2015-10-13 2020-08-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. BRD4-kinase inhibitors as cancer therapeutics
RS60981B1 (sr) 2015-12-18 2020-11-30 Janssen Pharmaceutica Nv Radiooznačeni mglur2/3 pet ligandi
EA037941B1 (ru) 2015-12-18 2021-06-09 Янссен Фармацевтика Нв ЛИГАНДЫ mGluR2/3 ДЛЯ PET, МЕЧЕННЫЕ РАДИОАКТИВНЫМИ ИЗОТОПАМИ
AU2017246455B2 (en) * 2016-04-06 2021-09-30 Bial - R&D Investments, S.A. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
CA3020310A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US10787454B2 (en) 2016-04-06 2020-09-29 BIAL—BioTech Investments, Inc. Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
AU2017261291C1 (en) 2016-05-05 2022-05-26 Bial - R&D Investments, S.A. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
WO2020081508A1 (en) 2018-10-15 2020-04-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017212A (en) * 1986-03-20 1991-05-21 Takeda Chemical Industries, Ltd. Sulfonylurea compounds and herbicidal use
PT891978E (pt) * 1997-07-18 2002-07-31 Hoffmann La Roche Derivados de 5h-tiazolo (3,2-a) pirimidina
KR20020047198A (ko) * 1999-09-30 2002-06-21 해피 페너 ; 해리 에이치. 페너 2세 특정 알킬렌 디아민-치환된피라졸로[1,5-ａ]-1,5-피리미딘 및피라졸로[1,5-ａ]-1,3,5-트리아진
KR20040111445A (ko) * 2002-03-28 2004-12-31 에자이 가부시키가이샤 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine

Also Published As

Publication number Publication date
IL179736A0 (en) 2007-05-15
PT1761541E (pt) 2008-03-13
ES2299044T3 (es) 2008-05-16
AU2005254657B2 (en) 2011-03-17
US20050282827A1 (en) 2005-12-22
DK1761541T3 (da) 2008-04-28
BRPI0512330A (pt) 2008-02-26
TW200626598A (en) 2006-08-01
AR049521A1 (es) 2006-08-09
IL179736A (en) 2010-12-30
DE602005004287D1 (de) 2008-02-21
RU2378277C2 (ru) 2010-01-10
RU2006143571A (ru) 2008-07-27
WO2005123738A1 (en) 2005-12-29
CA2571487C (en) 2013-04-30
NZ551660A (en) 2009-08-28
MY143368A (en) 2011-04-29
ZA200610102B (en) 2008-08-27
CN100528876C (zh) 2009-08-19
ATE383361T1 (de) 2008-01-15
JP4608542B2 (ja) 2011-01-12
HK1105971A1 (en) 2008-02-29
SI1761541T1 (sl) 2008-06-30
HRP20080070T3 (en) 2008-05-31
NO20070249L (no) 2007-02-15
CN1964973A (zh) 2007-05-16
US7378417B2 (en) 2008-05-27
EP1761541A1 (en) 2007-03-14
TWI301835B (en) 2008-10-11
DE602005004287T2 (de) 2008-12-24
CA2571487A1 (en) 2005-12-29
AU2005254657A1 (en) 2005-12-29
EP1761541B1 (en) 2008-01-09
JP2008503510A (ja) 2008-02-07
MXPA06014809A (es) 2007-02-12

Similar Documents

Publication Publication Date Title
TWI369356B (en) Tetrahydropyridoindole derivatives
IL180481A0 (en) Aryl-pyridine derivatives
HK1105971A1 (en) Pyrrazolo-pyrimidine derivatives
AP2074A (en) New 4-benzylidene-piperidin derivatives
IL180331A0 (en) 3-carbamoyl - 2 - pyridone derivative
HUS2000022I1 (hu) Tiglien-3-on származékok
EP1878727A4 (en) 2-AMINOQUINAZOLINE DERIVATIVES
IL185674A0 (en) 1-benzylindole-2-carboxamide derivatives
IL183140A0 (en) Substituted benzoquinolizine derivatives
ZA200703172B (en) Imidazo-benzodiazepine derivatives
IL177204A0 (en) Novel 4-benzimidazol -2-ylpyridazin -3- one derivatives
HK1101638A1 (en) New pyridothienopyrimidine derivatives
HK1100002A1 (en) 4-phenyl-pyrimidine-2-carbonitrile derivatives
IL183141A0 (en) New pyridothienopyrimidine derivatives
IL182739A0 (en) Acylatednonadepsipeptides used as lysobactin derivatives
HK1100775A1 (en) 4-Amino-5-cyanopyrimidine derivatives
GB0414272D0 (en) OsK1 derivatives
GB0511410D0 (en) Benzotrizepinone derivatives
IL182001A0 (en) 2-acylaminothiazole derivatives
GB0422397D0 (en) 3-Cyano-Quinoline derivatives
GB0405905D0 (en) Azaquinazoline derivatives
HUP0402371A2 (en) Novel 125-i-labeled amino-quinoline derivatives
GB0500900D0 (en) Azaquinazoline derivatives